Shuttle Pharmaceuticals Holdings, INC 8-K filings

Shuttle Pharmaceuticals Holdings, Inc. amended its Securities Purchase Agreement with Alto Opportunity Master Fund, waiving Alto's right to future investments in exchange for a $75,000 payment.

Shuttle Pharmaceuticals Holdings, Inc. provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2024, highlighting progress in clinical trials and diagnostic development.

Shuttle Pharmaceuticals increases patient enrollment and study sites for its Phase 2 trial of Ropidoxuridine in glioblastoma patients through a change order with Theradex Systems.

Shuttle Pharmaceuticals has reached 25% enrollment in the initial randomized portion of its Phase 2 clinical trial for Ropidoxuridine, a potential treatment for glioblastoma.

Shuttle Pharmaceuticals received a notice from Nasdaq for failing to maintain a minimum share price, while also announcing CEO participation in an upcoming investor summit.

Shuttle Pharmaceuticals has partnered with the University of California, San Francisco to further develop a prostate-specific membrane antigen (PSMA) ligand for potential diagnostic and therapeutic applications.

Shuttle Pharmaceuticals has expanded its Phase 2 clinical trial for Ropidoxuridine, with the first patient dosed at UVA Cancer Center for the treatment of glioblastoma.

Shuttle Pharmaceuticals announced a corporate update, highlighting the dosing of the first patients in a Phase 2 clinical trial for a brain tumor treatment and the completion of key financial transactions.

Shuttle Pharmaceuticals Holdings, Inc. has successfully priced a $4.5 million public offering to support its clinical trials and general corporate needs.

Shuttle Pharmaceuticals has successfully dosed the first three patients in its Phase 2 clinical trial of Ropidoxuridine for the treatment of glioblastoma.

Shuttle Pharmaceuticals has completed agreements with all six planned sites for its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment.

Shuttle Pharmaceuticals' CEO will present at the ThinkEquity Conference on October 30, 2024, discussing the company's clinical trial progress and pipeline developments.

Shuttle Pharmaceuticals Holdings, Inc. has finalized a $790,000 offering of convertible notes and warrants, including a significant investment from its CEO.

Shuttle Pharmaceuticals Holdings, Inc. has successfully closed on $600,000 of a planned $1.3 million convertible note and warrant offering to accredited investors.

Shuttle Pharmaceuticals Holdings, Inc. has received a notification from Nasdaq for not meeting the minimum stockholders' equity requirement for continued listing.

Shuttle Pharmaceuticals Holdings, Inc. has entered into a promissory note agreement with its CEO, Dr. Anatoly Dritschilo, for a $250,000 loan.

Shuttle Pharmaceuticals has commenced its Phase 2 clinical trial for Ropidoxuridine in glioblastoma patients and regained compliance with Nasdaq listing rules after a re-audit.

Shuttle Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement after its stock traded above $1.00 for ten consecutive days.

Shuttle Pharmaceuticals received a notice from Nasdaq for non-compliance with listing rules due to a delay in filing its quarterly report, stemming from a re-audit of prior financial statements.

Shuttle Pharmaceuticals has engaged a contract research organization and activated two clinical sites to advance its Phase 2 trial of Ropidoxuridine for glioblastoma treatment.

Shuttle Pharmaceuticals has amended its debt agreement, implemented a 1-for-8 reverse stock split, and plans an equity offering to fund upcoming clinical trials.

Shuttle Pharmaceuticals held its annual meeting, electing six directors, ratifying its auditors, approving executive compensation, and authorizing a reverse stock split.

Shuttle Pharmaceuticals has determined that its financial statements for 2022, 2023, and the first quarter of 2024 require restatement due to accounting errors related to stock compensation, convertible notes, and preferred stock.

Shuttle Pharmaceuticals has appointed Timothy Lorber as its new Chief Financial Officer, while current CFO Michael Vander Hoek will transition to a full-time Vice President of Regulatory role.

Shuttle Pharmaceuticals' CEO, Dr. Anatoly Dritschilo, will present at the Lytham Partners Spring 2024 Investor Conference, providing updates on their clinical trial for glioblastoma and diagnostic biomarker development.

Shuttle Pharmaceuticals announced FDA approval for its Phase 2 glioblastoma trial, progress in site enrollment, and the creation of a diagnostics subsidiary.

Shuttle Pharmaceuticals Holdings, Inc. announces its CEO will present at the Planet MicroCap Showcase in Las Vegas on May 1, 2024, and has released an updated investor presentation.

Shuttle Pharmaceuticals' CEO will present at the Planet MicroCap Showcase, discussing the company's Phase 2 clinical trial for glioblastoma and plans for its subsidiary, Shuttle Diagnostics.

Shuttle Pharmaceuticals has received FDA approval for a Phase 2 clinical trial of Ropidoxuridine and is expanding into diagnostics with a new subsidiary and intellectual property licenses.

Shuttle Pharmaceuticals has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement and the CEO will present at the Emerging Growth Conference.